Safety Concerns and Labeling Changes for Psoriasis Drug Raptiva
Mon, 20 Oct 2008 07:20:00 -0500
FDA has received reports of serious infections leading to hospitalizations and deaths in people who use Raptiva.
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
Look for the "Printer-friendly PDF" link in the upper right corner of select articles; this feature makes it easy to distribute copies. Text of articles published on FDA's Consumer page may be republished without permission. Credit to "FDA Consumer Health Information" as the source is appreciated.
Visit FDA's Consumer page: http://www.fda.gov/consumer/
Send story ideas to: fdaconsumerlist@xxxxxxxxxx
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
